Boston Scientific Corporation
BSX
$51.08
$0.621.23%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 906.00M | 1.34B | 672.00M | 755.00M | 797.00M |
| Total Depreciation and Amortization | 355.00M | 351.00M | 365.00M | 342.00M | 336.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 139.00M | -429.00M | 172.00M | 202.00M | -80.00M |
| Change in Net Operating Assets | 74.00M | -915.00M | 155.00M | 44.00M | 233.00M |
| Cash from Operations | 1.47B | 348.00M | 1.36B | 1.34B | 1.29B |
| Capital Expenditure | -195.00M | -177.00M | -351.00M | -181.00M | -157.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -195.00M | -523.00M | -89.00M | -256.00M | -1.01B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.57B | 109.00M | -72.00M | -65.00M | 40.00M |
| Cash from Investing | -1.96B | -591.00M | -512.00M | -502.00M | -1.13B |
| Total Debt Issued | 1.68B | -- | 0.00 | 0.00 | 1.00M |
| Total Debt Repaid | -13.00M | -259.00M | -209.00M | -215.00M | -314.00M |
| Issuance of Common Stock | 5.00M | 81.00M | 20.00M | 115.00M | 32.00M |
| Repurchase of Common Stock | -2.00B | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.00M | -82.00M | 5.00M | -4.00M | -59.00M |
| Cash from Financing | -410.00M | -260.00M | -184.00M | -104.00M | -340.00M |
| Foreign Exchange rate Adjustments | 1.00M | -- | 3.00M | -2.00M | 2.00M |
| Miscellaneous Cash Flow Adjustments | 1.00M | -1.00M | -- | -- | -- |
| Net Change in Cash | -890.00M | -504.00M | 671.00M | 735.00M | -178.00M |